




RealRate

PHARMACEUTICAL 2016

Lexaria Bioscience Corp
Rank 260 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lexaria Bioscience Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Lexaria Bioscience Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 247% points.

The company's Economic Capital Ratio, given in the ranking table, is 120%, being 144% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	675
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55
Liabilities, Non-Current	0
Other Assets	37
Other Compr. Net Income	0
Other Expenses	1,833
Other Liabilities	0
Other Net Income	0
Other Revenues	15
Property and Equipment	0
Research and Development	146
Selling, General and Administrative Expense	19

Output Variable	Value in 1000 USD
Assets	712
Liabilities	55
Expenses	1,998
Revenues	15
Stockholders Equity	657
Net Income	-1,983
Comprehensive Net Income	-1,983
BaseVar	1,390
ECR before Limited Liability	-144%
Economic Capital Ratio	120%